FIELD: immunology.
SUBSTANCE: disclosed is an antibody which specifically binds to the E. coli strains antigen O25b. Disclosed is use of such an antibody for treating a patient at risk or suffering from an infection caused by O25b-positive E. coli strains, a pharmaceutical preparation, kit and method for infection diagnosis. Besides, there is presented a nucleic acid coding antibody, expression cassettes, plasmids, a host cell and a method for producing the antibody.
EFFECT: present invention can find further application in the diagnosis and therapy of O25b-positive Escherichia coli strains.
19 cl, 10 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
ANTI-VSIG4 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF | 2020 |
|
RU2826236C1 |
ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
Authors
Dates
2020-06-23—Published
2014-12-19—Filed